Drug Details

General Information of the Drug (ID: DR5656)
Name
Loxoprofen
Synonyms
Loxoprofen; 68767-14-6; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; Loxoprofene; Loxoprofeno; Koloxo; Loxoprofenum; Loxoprofen [INN]; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; UNII-3583H0GZAP; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; MFCD00864331; CHEMBL19299; 3583H0GZAP; Loxoprofen sodium hydrate; CHEBI:76172; CS-600; sodium loxoprofen; Loxoprofen (INN); Oxeno; NCGC00015594-02; DSSTox_CID_25164; DSSTox_RID_80714; DSSTox_GSID_45164; Loxoprofene [French]; Loxoprofenum [Latin]; Loxoprofeno [Spanish]; yl]-propionic acid; CAS-68767-14-6; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; Loxoprofen, solid; 80382-23-6; Lopac0_000677; SCHEMBL24423; C15H17NaO3; (+-)-p-((2-Oxocyclopentyl)methyl)hydratropic acid; DTXSID1045164; alpha-Methyl-4-[(2-oxocyclopentyl)methyl]benzeneacetic acid; HMS3262G15; HMS3885N16; Loxoprofen (low-melting polymorph); BCP10971; EBD24378; HY-B0578; Loxoprofen (high-melting polymorph); Tox21_110178; Tox21_500677; ANW-43655; BDBM50140320; s4682; AKOS015906359; Tox21_110178_1; AC-8108; AT-7141; CCG-204763; DB09212; GS-3193; LP00677; SDCCGSBI-0050656.P002; NCGC00015594-03; NCGC00015594-04; NCGC00015594-08; NCGC00094037-01; NCGC00094037-02; NCGC00261362-01; NCGC00263577-01; AC-15776; AK-72809; H883; SY113439; AB0012364; DB-055188; EU-0100677; FT-0641207; L0244; CS-600; CS600; CS 600; D08149; L 0664; M-9376; (+-)-((2-oxocyclopentyl)methyl)hydratropic acid; 767L146; A836244; SR-01000075955; Q-201324; Q-300011; Q2759348; SR-01000075955-1; 2-[4-[(2-Oxocyclopentyl)methyl]phenyl]propionic Acid; 2-(4-((2-Oxocyclopentyl)methyl)-phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phenyl]-propionic acid; 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl]propionic acid; 2-[4-(2-Oxocyclopentan-1-ylmethyl)phenyl]-propionic Acid; 2-[4-[(2-oxidanylidenecyclopentyl)methyl]phenyl]propanoic acid; Benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-; Benzeneacetic acid, .alpha.-methyl-4-[(2-oxocyclopentyl)methyl]-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Ankylosing spondylitis [ICD-11: FA92] Phase 4 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Bioavailability
The bioavailability of drug is 0.64%
Elimination
50% of drug renal excretion, and 20% - 30% of drug is excreted in the stool
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours
Metabolism
The drug is metabolized via the carbonyl reductase in the liver
Vd
The volume of distribution (Vd) of drug is 0.16 L/kg
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C15H18O3
PubChem CID
3965
Canonical SMILES
CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
InChI
1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
InChIKey
YMBXTVYHTMGZDW-UHFFFAOYSA-N
CAS Number
CAS 68767-14-6
ChEBI ID
CHEBI:76172
DrugBank ID
DB09212
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Glycine      Musa x paradisiaca     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Female Sprague-Dawley rats, weighing 200-250 g (10-12-week-old), were used in this study.
                    Experimental
                    Result(s)		 The combined administration of loxoprofen and glycine produced a synergistic inhibitory effect on the micturition reflex.
Target and Pathway
Target(s) Prostaglandin G/H synthase 1 (COX-1)  Molecule Info  [3]
Prostaglandin G/H synthase 2 (COX-2)  Molecule Info  [3]
BioCyc Aspirin-triggered lipoxin biosynthesis Click to Show/Hide
2 Aspirin triggered resolvin D biosynthesis
3 C20 prostanoid biosynthesis
4 Aspirin triggered resolvin E biosynthesis
KEGG Pathway Arachidonic acid metabolism Click to Show/Hide
2 Metabolic pathways
3 NF-kappa B signaling pathway
4 VEGF signaling pathway
5 TNF signaling pathway
6 Retrograde endocannabinoid signaling
7 Serotonergic synapse
8 Ovarian steroidogenesis
9 Oxytocin signaling pathway
10 Regulation of lipolysis in adipocytes
11 Leishmaniasis
12 Pathways in cancer
13 Chemical carcinogenesis
14 MicroRNAs in cancer
15 Small cell lung cancer
16 Platelet activation
NetPath Pathway IL1 Signaling Pathway Click to Show/Hide
2 TSH Signaling Pathway
3 IL4 Signaling Pathway
4 TGF_beta_Receptor Signaling Pathway
5 IL5 Signaling Pathway
Panther Pathway Endothelin signaling pathway Click to Show/Hide
2 Inflammation mediated by chemokine and cytokine signaling pathway
3 Toll receptor signaling pathway
4 CCKR signaling map ST
Pathwhiz Pathway Arachidonic Acid Metabolism Click to Show/Hide
Pathway Interaction Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes Click to Show/Hide
2 S1P1 pathway
3 C-MYB transcription factor network
4 Signaling mediated by p38-alpha and p38-beta
5 Calcium signaling in the CD4+ TCR pathway
WikiPathways Prostaglandin Synthesis and Regulation Click to Show/Hide
2 Arachidonic acid metabolism
3 Aryl Hydrocarbon Receptor
4 Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
5 Spinal Cord Injury
6 Integrated Pancreatic Cancer Pathway
7 Eicosanoid Synthesis
8 Selenium Micronutrient Network
9 Phase 1 - Functionalization of compounds
References
Reference 1 ClinicalTrials.gov (NCT03800797) Efficacy and Safety of Loxoprofen Hydrogel Patch in Patients With Ankylosing Spondylitis
Reference 2 Synergistic effects of loxoprofen and glycine on the micturition reflex in conscious rats. Biomed Res. 2014;35(1):17-23.
Reference 3 Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004 Mar 8;14(5):1201-3.
 Download Picture         KEGG Link